WT1, WTX and CTNNB1 mutation analysis in 43 patients with sporadic Wilms' tumor

Cardoso,Leila  C.A.; De Souza,Kelly  R.L.; De O. Reis,Adriana  Helena; Andrade,Raissa  Coelho; Britto ,Alberto  C.; De Lima,Maria  A.F.D.; Dos Santos,Anna  C.E.; De Faria,Paulo  S.; Ferman,Sima; Seuánez,Héctor  N.; Vargas,Fernando  R.

doi:10.3892/or.2012.2096

WT1, WTX and CTNNB1 mutation analysis in 43 patients with sporadic Wilms' tumor

Authors:
- Leila C.A. Cardoso
- Kelly R.L. De Souza
- Adriana Helena De O. Reis
- Raissa Coelho Andrade
- Alberto C. Britto
- Maria A.F.D. De Lima
- Anna C.E. Dos Santos
- Paulo S. De Faria
- Sima Ferman
- Héctor N. Seuánez
- Fernando R. Vargas
View Affiliations

Affiliations: Department of Genetics, Federal University of Rio de Janeiro, Rio de Janeiro, RJ, 21944‑970, Brazil, Genetics Program, National Institute of Cancer, Rio de Janeiro, RJ, 20231‑050, Brazil, Department of Genetics, Federal University of Rio de Janeiro, Rio de Janeiro, RJ, 21944‑970, Brazil, Pathology Division, National Institute of Cancer, Rio de Janeiro, RJ, 20220-400, Brazil, Department of Pediatric Oncology, National Institute of Cancer, Rio de Janeiro, RJ, 20230‑130, Brazil
Published online on: October 19, 2012 https://doi.org/10.3892/or.2012.2096
Pages: 315-320

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Wilms' tumor (WT) is a heterogeneous neoplasia characterized by a number of genetic abnormalities, involving tumor suppressor genes, oncogenes and genes related to the Wnt signaling pathway. Somatic biallelic inactivation of WT1 is observed in 5-10% of sporadic WT. Somatic mutations in exon 3 of CTNNB1, which encodes β-catenin, were initially observed in 15% of WT. WTX encodes a protein that negatively regulates the Wnt/β-catenin signaling pathway and mediates the binding of WT1. In this study, we screened germline and somatic mutations in selected regions of WT1, WTX and CTNNB1 in 43 WT patients. Mutation analysis of WT1 identified two single-nucleotide polymorphisms, one recurrent nonsense mutation (p.R458X) in a patient with proteinuria but without genitourinary findings of Denys-Drash syndrome (DDS) and one novel missense mutation, p.C428Y, in a patient with Denys-Drash syndrome phenotype. WT1 SNP rs16754A>G (R369R) was observed in 17/43 patients, and was not associated with significant difference in age at diagnosis distribution, or with 60-month overall survival rate. WTX mutation analysis identified five sequence variations, two synonymous substitutions (p.Q1019Q and p.D379D), a non-synonymous mutation (p.F159L), one frameshift mutation (p.157X) and a novel missense mutation, p.R560W. Two sequence variations in CTNNB1 were identified, p.T41A and p.S45C. Overall survival of bilateral cases was significantly lower (p=0.005). No difference was observed when survival was analyzed among patients with WT1 or with WTX mutations. On the other hand, the survival of two patients with the CTNNB1 p.T41A mutation was significantly lower (p=0.000517) than the average.

View Figures

View References

1	Dome JS and Huff V: Wilms Tumor Overview. GeneReviews. Pagon RA, Bird TD, Dolan CB and Stephans K: University of Washington; Seattle: 2011
2	Rivera MN, Kim WJ, Wells J, et al: An X chromosome gene, WTX, is commonly inactivated in Wilms tumor. Science. 315:642–645. 2007. View Article : Google Scholar : PubMed/NCBI
3	Haber DA, Sohn RL, Buckler AJ, Pelletier J, Call KM and Housman DE: Alternative splicing and genomic structure of the Wilms tumor gene WT1. Proc Natl Acad Sci. 88:9618–9622. 1991. View Article : Google Scholar : PubMed/NCBI
4	Lamond AI: RNA processing. Wilms’ tumour - the splicing connection? Curr Biol. 5:862–865. 1995.
5	Wells J, Rivera MN, Kim WJ, Starbuck K and Haber DA: The predominant WT1 isoform (+KTS) encodes a DNA binding protein targeting the planar cell polarity gene Scribble in renal podocytes. Mol Cancer Res. 8:975–985. 2010.
6	Huff V: Wilms’ tumours: about tumour suppressor genes, an oncogene and a chameleon gene. Nature. 11:111–121. 2011.
7	Pelletier J, Bruening W, Kashtan CE, et al: Germline mutations in the Wilms’ tumor suppressor gene are associated with abnormal urogenital development in Denys-Drash syndrome. Cell. 67:437–447. 1991.
8	Koesters R, Ridder R, Kopp-Schneider AK, et al: Mutational activation of the β-catenin proto-oncogene is a common event in the development of Wilms’ tumors. J Cancer Res. 59:3880–3882. 1999.
9	Maeda O, Usami N, Kondo M, et al: Plakoglobin (γ-catenin) has TCF/LEF family - dependent transcriptional activity in beta-catenin-deficient cell line. Oncogene. 23:964–972. 2004.
10	Oloumi A, McPhee T and Dedhar S: Regulation of E-cadherin expression and beta-catenin/Tcf transcriptional activity by the integrin-linked kinase. Biochim Biophys Acta. 1691:1–15. 2004. View Article : Google Scholar : PubMed/NCBI
11	Clevers H: Wnt/beta-catenin signaling in development and disease. Cell. 127:469–480. 2006. View Article : Google Scholar : PubMed/NCBI
12	Major MB, Camp ND, Berndt JD, et al: Wilms tumor supressor WTX negatively regulates Wnt/β-catenin signaling. Science. 316:1043–1046. 2007.
13	Rivera MN, Kim WJ, Wells J, Stone A, et al: The tumor suppressor WTX shuttles to the nucleus and modulates WT1 activity. Proc Natl Acad Sci USA. 106:8338–8343. 2009. View Article : Google Scholar : PubMed/NCBI
14	Miller SA, Dykes DD and Polesky HF: A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res. 16:12151988. View Article : Google Scholar : PubMed/NCBI
15	Sambrook J, Fritsch EF and Maniatis T: Molecular Cloning: A Laboratory Manual. 2nd edition. Cold Spring Harbor; New York: 1989
16	Nacional Center for Biotechnology Information. http://www.ncbi.nlm.nih.gov/:. Accessed April 14, 2012
17	Milani L, Gupta M, Andersen M, et al: Allelic imbalance in gene expression as a guide to cis-acting regulatory single nucleotide polymorphisms in cancer cells. Nucleic Acids Res. 35:e34–e43. 2007. View Article : Google Scholar : PubMed/NCBI
18	Ho PA, Kuhn J, Gerbing RB, et al: WT1 synonymous single nucleotide polymorphism rs16754 correlates with higher mRNA expression and predicts significantly improved outcome in favorable-risk pediatric acute myeloid leukemia: a report from the children’s oncology group. J Clin Oncol. 29:704–711. 2011.PubMed/NCBI
19	Splice-Site Analyzer Tool. Genome Bioinformatics group of University of California Santa Cruz: Splice-Site analyzer tool. http://ibis.tau.ac.il/ssat/SpliceSiteFrame.htm. Accessed January 20, 2012
20	Royer-Pokora B, Beier M, Henzler M, Alan R, Schumacher V, Weirich A and Huff V: Twenty-four new cases of WT1 germline mutations and review of the literature: genotype/phenotype correlations for Wilms tumor development. Am J Med Genet A. 127:249–257. 2004.
21	Kohsaka T, Tagawa M, Takekoshi Y, Yanagisawa H, Tadokoro K and Yamada M: Exon 9 mutations in the WT1 gene, without influencing KTS splice isoforms, are also responsible for Frasier syndrome. Hum Mutat. 14:466–470. 1999.PubMed/NCBI
22	Little MH, Prosser J, Condie A, Smith PJ, Van Heyningen V and Hastie ND: Zinc finger point mutations within the WT1 gene in Wilms tumor patients. Proc Natl Acad Sci USA. 89:4791–4795. 1992. View Article : Google Scholar : PubMed/NCBI
23	Schumacher V, Schneider S, Figge A, et al: Correlation of germ-line mutations and two-hit inactivation of the WT1 gene with Wilms tumors of stromal-predominant histology. Proc Natl Acad Sci USA. 94:3972–3977. 1997. View Article : Google Scholar : PubMed/NCBI
24	Maiti S, Alam R, Amos CI and Huff V: Frequent association of β-catenin and WT1 mutations in Wilms tumors. Cancer Res. 60:6288–6292. 2000.
25	Shibata R, Hashiguchi A, Sakamoto J, Yamada T, Umezawa A and Hata J: Correlation between a specific Wilms tumour suppressor gene (WT1) mutation and the histological findings in Wilms tumour (WT). J Med Genet. 39:e832002. View Article : Google Scholar : PubMed/NCBI
26	Little SE, Hanks SP, King-Underwood L, et al: Frequency and heritability of WT1 mutations in nonsyndromic Wilms’ tumor patients: a UK Children’s Cancer Study Group Study. J Clin Oncol. 22:4140–4146. 2004.PubMed/NCBI
27	Corbin M, de Reyniès A, Rickman DS, et al: WNT/β-catenin pathway activation in Wilms tumors: a unifying mechanism with multiple entries? Genes Chromosomes Cancer. 48:816–827. 2009.
28	Little MH, Williamson KA, Mannens M, Kelsey A, Gosden C, Hastie ND and van Heyningen V: Evidence that WT1 mutations in Denys-Drash syndrome patients may act in a dominant-negative fashion. Hum Mol Genet. 2:259–264. 1993.
29	Royer-Pokora B, Weirich A, Schumacher V, et al: Clinical relevance of mutations in the Wilms tumor suppressor 1 gene WT1 and the cadherin-associated protein β1 gene CTNNB1 for patients with Wilms tumors. Results of long-term surveillance of 71 patients from International Society of Pediatric Oncology Study 9/Society for Pediatric Oncology. Cancer. 113:1080–1089. 2008. View Article : Google Scholar : PubMed/NCBI
30	Jenkins ZA, van Kogelenberg M, Morgan T, et al: Germline mutations in WTX cause a sclerosing skeletal dysplasia but do not predispose to tumorigenesis. Nat Genet. 41:95–100. 2009. View Article : Google Scholar : PubMed/NCBI
31	Perotti D, Gamba B, Sardella M, et al: Functional inactivation of the WTX gene is not a frequent event in Wilms’ tumors. Oncogene. 27:4625–4632. 2008.PubMed/NCBI
32	Wegert J, Wittmann S, Leuschner I, Geissinger E, Graf N and Gessler M: WTX inactivation is a frequent, but late event in Wilms tumors without apparent clinical impact. Genes Chromosomes Cancer. 48:1102–1111. 2009. View Article : Google Scholar : PubMed/NCBI
33	Ruteshouser EC, Robinson SM and Huff V: Wilms tumor genetics: mutations in WT1, WTX, and CTNNB1 account for only about one-third of tumors. Genes Chromosomes Cancer. 47:461–470. 2008.PubMed/NCBI
34	Fukuzawa R, Anaka MR, Weeks RJ, Morison IM and Reeve AE: Canonical WNT signaling determines lineage specificity in Wilms tumour. Oncogene. 28:1063–1075. 2009. View Article : Google Scholar : PubMed/NCBI
35	Fukuzawa R, Holman SK, Chow CW, Savarirayan R, Reeve AE and Robertson SP: WTX mutations can occur both early and late in the pathogenesis of Wilms tumour. J Med Genet. 47:791–794. 2010. View Article : Google Scholar : PubMed/NCBI
36	Haruta M, Arai Y, Watanabe N, et al: Different incidences of epigenetic but not genetic abnormalities between Wilms tumors in Japanese and Caucasian children. Cancer Sci. 103:1129–1135. 2012. View Article : Google Scholar : PubMed/NCBI
37	Scott RH, Murray A, Baskcomb L, Turnbull C, et al: Stratification of Wilms tumor by genetic and epigenetic analysis. Oncotarget. 3:327–335. 2012.PubMed/NCBI
38	Perdu B, Lakeman P, Mortier G, Koenig R, Lachmeijer A and Van Hul W: Two novel WTX mutations underscore the unpredictability of male survival in osteopathia striata with cranial sclerosis. Clin Genet. 80:383–388. 2010.
39	Li CM, Kim CE, Margolin AA, Guo M, et al: CTNNB1 mutations and overexpression of Wnt/β-catenin target genes in WT1-mutant Wilm’s tumors. Am J Pathol. 165:1943–1953. 2004.
40	Uschkereit C, Perez N, de Torres C, Küff M, Mora J and Royer-Pokora B: Different CTNNB1 mutations as molecular genetic proof for the independent origin of four Wilms tumours in a patient with a novel germ line WT1 mutation. J Med Genet. 44:393–396. 2007.